Piperacetazine

Summary

Piperacetazine (CHEMBL1584) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 410.6 Da · C24H30N2O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1584
Name	Piperacetazine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	19675
Molecular formula	C24H30N2O2S
Molecular weight	410.6
InChIKey	BTFMCMVEUCGQDX-UHFFFAOYSA-N

SMILES: CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCC(CC4)CCO

IUPAC name: 1-[10-[3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl]phenothiazin-2-yl]ethanone

Also known as: NSC-760067, PC-1421, Piperacetazina, Piperacetazine, Quide, SID11112549, PIPERACETAZINE, SID56463171, SID144204091, SID170465363, piperacetazine

Patent coverage: 1,781 distinct patent families (3,340 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,271 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 24 (assay-derived). Sample: Ubiquitin carboxyl-terminal hydrolase 2, 5-hydroxytryptamine receptor 2B, Protein deacetylase HDAC6, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Menin/Histone-lysine N-methyltransferase MLL, Beta-2 adrenergic receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1.

Bioactivity

ChEMBL activities: 24 potent at pChembl ≥ 5 of 28 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR2A	7.92	AC50	12	nM	CHEMBL_ACT_25173702
DRD2	7.89	AC50	13	nM	CHEMBL_ACT_25140598
DRD3	7.77	AC50	17	nM	CHEMBL_ACT_25193787
HRH1	7.47	AC50	34	nM	CHEMBL_ACT_25212777
HTR1A	7.38	AC50	42.1	nM	CHEMBL_ACT_25164587
HTR1A	7.37	AC50	43	nM	CHEMBL_ACT_25216204
ADRA2B	7.17	AC50	68	nM	CHEMBL_ACT_25143959
ADRA1A	6.85	AC50	140	nM	CHEMBL_ACT_25218259
ADRA1A	6.75	AC50	180	nM	CHEMBL_ACT_25138080
CYP2D6	6.7	Potency	199.5	nM	CHEMBL_ACT_4973928
CYP2D6	6.7	AC50	199.5	nM	CHEMBL_ACT_6071450
HTR2A	6.52	AC50	300	nM	CHEMBL_ACT_25225412
ADRA2C	6.43	AC50	370	nM	CHEMBL_ACT_25148144
KCNH2	6.3	AC50	500	nM	CHEMBL_ACT_25118242
SLC6A4	5.89	AC50	1300	nM	CHEMBL_ACT_25150590
SLC6A2	5.75	AC50	1800	nM	CHEMBL_ACT_25145258
HDAC6	5.66	IC50	2187	nM	CHEMBL_ACT_23141090
OPRK1	5.4	AC50	4000	nM	CHEMBL_ACT_25129670
HTR2B	5.33	AC50	4700	nM	CHEMBL_ACT_25227775
USP2	5.3	Potency	5012	nM	CHEMBL_ACT_4747768
CYP1A2	5.2	AC50	6310	nM	CHEMBL_ACT_6060014
SLC6A3	5.12	AC50	7600	nM	CHEMBL_ACT_25124210
CHRM1	5.1	AC50	7900	nM	CHEMBL_ACT_25135722
CHRM3	5.02	AC50	9500	nM	CHEMBL_ACT_25136940

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).